This session highlights advancements in managing coronary calcified lesions through intravascular lithotripsy using the Shockwave system. It discusses the unique mechanism of action for different calcium morphologies, reviews the latest clinical data, and addresses complex scenarios including diffuse lesions and challenging nodular or eccentric calcium deposits,...

Delve into advanced transcatheter aortic valve implantation (TAVI) with the Evolut FX plus system, focusing on its application in patients with small annulus and coronary artery disease (CAD). This session details step-by-step deployment, patient selection, imaging analysis, and highlights the distinctions from the previous Evolut R...

Focus on the evolving role of drug-coated balloons (DCB) in complex PCI, extending their use beyond traditional indications to challenging coronary lesions and high-risk patient populations. This session reviews clinical data from the SCAAR Prevail registry and discusses the evidence journey supporting broader advocacy for DCB...

Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the...

EuroPCR, the annual world-leading Course in interventional cardiovascular medicine, has been taking place for over 30 years. It is tailored for all those dedicated to the sharing of knowledge and skills, and improvement of patient care worldwide: interventional cardiologists, cardiac surgeons, imaging specialists, radiologists, nurses, allied...

In collaboration with EuroIntervention Journal

The authors decided to create a survey tailored for ICTs in order to assess the changes in their training. Capturing the essence of the responses may help to identify the most appropriate strategies to provide the highest standards and skills achievements in COVID-19...

Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)